DENVER, Colo. (247marketnews.com) – The market is getting a fresh reminder that the biggest opportunities are increasingly being built around AI, cybersecurity, advanced medicine and the infrastructure required to commercialize them. Propanc Biopharma (NASDAQ:PPCB), Celularity (NASDAQ:CELU), NeOnc Technologies (NASDAQ:NTHI), Salesforce (NYSE:CRM), CrowdStrike (NASDAQ:CRWD), and Okta (NASDAQ:OKTA).
Propanc Biopharma
Propanc Biopharma (NASDAQ:PPCB) is entering one of the most consequential stretches in its development story after reporting new preclinical data showing greater than 90% mean tumor-growth inhibition in orthotopic and patient-derived xenograft models of pancreatic ductal adenocarcinoma. The company also reported reduced metastatic burden, changes to the tumor microenvironment and a greater than 2.5-fold extension in median overall survival in treated animals.
The timing matters. The pancreatic-cancer market has just received a major demonstration of what successful innovation can potentially mean commercially. Revolution Medicines' (NASDAQ:RVMD) daraxonrasib has emerged as a major RAS-targeted development, while Propanc is pursuing a fundamentally different mechanism involving pancreatic proenzymes and cancer-cell differentiation. Propanc's August 12 release explicitly positioned PRP against RAS-targeted approaches from Revolution Medicines and Erasca.
But the next catalyst may be even more important than the animal data: Propanc is moving toward human testing. On August 18, the company announced that Avance Clinical would lead preparations for a first-in-human Phase 1b study of PRP involving up to 40 patients with advanced solid tumors.
That creates a clean speculative biotech narrative: striking preclinical results, an enormous unmet medical need, a differentiated mechanism and an approaching clinical transition. None of that guarantees clinical success, but the company is moving from a laboratory-stage story toward the much more valuable question of whether PRP can reproduce its biological promise in humans.
Celularity
Celularity (NASDAQ:CELU) may have opened a potentially important second revenue lane with MuseCell Innovations. The companies announced a U.S. manufacturing collaboration under which Celularity will establish production of Dezawa MuseCells and related products at its Florham Park, New Jersey facility. The program is also intended to encompass Dezawa MuseExosomes and Dezawa MuseSecretome.
The headline number is substantial: MuseCell Innovations believes the expanded relationship could generate more than $300 million of aggregate purchases from Celularity over five years. If that projection materializes evenly, it would represent an average of more than $60 million per year in potential purchases.
Celularity already operates a 147,215-square-foot purpose-built facility with multiple manufacturing suites and capabilities spanning process development, CMC, cell manufacturing, analytical methods and quality systems. That means the collaboration potentially puts existing infrastructure to work for an outside platform rather than relying exclusively on the company's internally developed pipeline.
Robert J. Hariri, Celularity's founder, chairman and CEO, described the agreement as demonstrating how the company's manufacturing infrastructure and cellular expertise can “support innovative third-party technologies.” Peter Diamandis added that the ability to manufacture advanced cellular technologies “reproducibly and at scale” is fundamental to the future of medicine.
For investors, the interesting question is therefore bigger than whether MuseCell becomes a major product platform. Can Celularity become part of the manufacturing infrastructure behind other companies' cellular-medicine ambitions? If the projected purchases develop, that could give CELU an additional commercial dimension while utilizing an asset the company has already built.
NeOnc Technologies
NeOnc (NASDAQ:NTHI) has moved into a dramatically different phase following positive topline Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma. The company reported 48.9% six-month progression-free survival, versus a prespecified 20% benchmark, with a reported p-value of 0.0047. Median overall survival was 26.09 months, while 86.7% of patients were alive at six months.
Importantly, the company is not stopping at the data release. NeOnc says it plans to request a Type B meeting with the FDA to align on a potential registrational pathway in a setting where it says there is no approved targeted therapy. That regulatory conversation could become the next major catalyst because it moves the story from “Did NEO100 generate interesting data?” toward “What does the FDA require to potentially register it?”
The company's approach is also designed around one of the central problems in CNS drug development: getting therapeutics into the brain. NEO100 is administered intranasally, and NeOnc says the Phase 2a study produced no major toxicities, with adverse events predominantly low-grade. Thomas C. Chen, M.D., Ph.D., described the results as “a powerful validation of the science behind NEO100.”
There is more behind the lead program. NEO212 has already completed Phase 1, with a recommended Phase 2 dose established at 610 mg, while the company has also received FDA written feedback concerning NEO212's CMC development.
For NTHI, the investment story has consequently shifted from platform potential toward clinical evidence plus regulatory execution. The risks remain, Phase 2 success does not guarantee Phase 3 success or approval, but the company now has a defined clinical dataset and a clearly articulated next regulatory objective.
Salesforce
Salesforce (NYSE:CRM) and Anthropic are pushing enterprise AI another step forward with Claudeforce, an expanded partnership designed to put Claude's reasoning capabilities directly against Salesforce data, workflows, business rules and governed actions. Salesforce says the initial launch includes a Salesforce plugin for Claude with 37 prebuilt sales skills.
The significance is strategic. Instead of asking employees to move between an AI assistant and enterprise software, the companies are attempting to make the AI operate directly against the systems where the business actually runs. Salesforce says the companies plan additional integrations across Claude, Salesforce and Slack.
Marc Benioff called the combination a fusion of Claude's reasoning with “the trusted data, workflows, and governance every enterprise runs on.” Anthropic CEO Dario Amodei similarly described the partnership as bringing frontier intelligence into systems where much of the world's commercial activity occurs.
The market is already responding to the broader thesis. Reuters reported that Salesforce raised its fiscal 2027 revenue and profit forecasts while announcing Claudeforce, with AI products including Agentforce, Data 360 and Slack contributing to the company's growth outlook.
The bigger narrative is therefore not simply “Salesforce adds Claude.” It is the possibility that enterprise applications become increasingly invisible while AI agents become the interface through which employees actually operate those applications.
CrowdStrike
CrowdStrike (NASDAQ:CRWD) delivered what management called the company's best quarter in its history, reporting $1.47 billion of revenue, up 26% year over year, and ending ARR of $5.84 billion, up 25%. Net new ARR reached a record $333 million.
The numbers become even more interesting when viewed through the AI-security lens. CrowdStrike said ARR from accounts adopting Falcon Flex exceeded $2.29 billion, representing 101% year-over-year growth. The company also generated $377 million of free cash flow during the quarter.
CEO George Kurtz said: “Every enterprise will run on AI, and securing it is the largest market opportunity in our history.” That statement captures the central investment argument: as AI expands the attack surface, companies may need to spend more—not less—on security.
Management subsequently raised its full-year FY2027 net-new-ARR growth outlook to 34% at the midpoint, a 630-basis-point increase. Reuters reported that CrowdStrike shares rose more than 10% in after-hours trading following the results as investors reacted to the stronger outlook and cybersecurity demand.
The takeaway is straightforward: AI is not merely creating a new software market; it is potentially expanding the market for software that protects every other AI deployment.
Okta (NASDAQ:OKTA) is approaching the AI boom from a different angle: identity. The company reported second-quarter FY2027 revenue of $805 million, up 11%, while subscription revenue increased 12%. More importantly, remaining performance obligations rose 17% to $4.858 billion, providing a substantial backlog of contracted subscription business.
Profitability also strengthened. Okta reported $107 million of GAAP operating income, compared with $41 million a year earlier, while free cash flow climbed to $227 million, or 28% of revenue. Full-year guidance calls for approximately $3.216 billion to $3.226 billion of revenue and $910 million to $930 million of free cash flow.
But CEO Todd McKinnon is framing the next opportunity around something increasingly important as autonomous AI spreads: every agent needs an identity and permissions. He said, “As AI agents transform every layer of technology, every agent needs a trusted identity and clear controls over what it can access and do.”
That puts Okta at an increasingly important intersection. Salesforce is building agents that act on enterprise data. CrowdStrike is securing AI deployments. Anthropic is supplying reasoning. Okta is arguing that none of those agents can safely operate at scale without authentication, authorization and governance.
The numbers suggest the market is already paying for that infrastructure: $4.858 billion in RPO, $2.585 billion in current RPO and 28% non-GAAP free-cash-flow margin give OKTA a financial base from which to pursue the expanding AI-identity opportunity.
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact [email protected] to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor. For further information, please visit 247mnn.com.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
[email protected]
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.